Sculptor Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Sculptor Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Hold	500,000	–	–	﹤0.01%	392
2026 Q1	$9.1K	Hold	500,000	–	–	﹤0.01%	346
2025 Q4	$9.82K	Hold	500,000	–	–	﹤0.01%	373
2025 Q3	$14K	Hold	500,000	–	–	﹤0.01%	347
2025 Q2	$22.5K	Sell	500,000 -1,905,000	-79%	-$94.1K	﹤0.01%	352
2025 Q1	$36.5K	Buy	2,405,000 +1,905,000	+381%	+$115K	﹤0.01%	290
2024 Q4	$20.6K	Hold	500,000	–	–	﹤0.01%	298
2024 Q3	$18.9K	Hold	500,000	–	–	﹤0.01%	287
2024 Q2	$18.7K	Hold	500,000	–	–	﹤0.01%	272
2024 Q1	$17.3K	Hold	500,000	–	–	﹤0.01%	284
2023 Q4	$32.5K	Hold	500,000	–	–	﹤0.01%	270
2023 Q3	$24.8K	Hold	500,000	–	–	﹤0.01%	305
2023 Q2	$27.5K	Hold	500,000	–	–	﹤0.01%	317
2023 Q1	$22.5K	Hold	500,000	–	–	﹤0.01%	408
2022 Q4	$20.3K	Hold	500,000	–	–	﹤0.01%	608
2022 Q3	$73K	Hold	500,000	–	–	﹤0.01%	728
2022 Q2	$80K	Buy	+500,000	New	+$109K	﹤0.01%	820

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Sculptor Capital's ASBPW Position: Q2 2026 in Review

Sculptor Capital held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 500,000 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Sculptor Capital first reported a position in ASBPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $80K in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Sculptor Capital held 500,000 shares of Aspire Biopharma Warrant worth $10K as of Q2 2026.
Sculptor Capital left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Sculptor Capital's portfolio in Q2 2026, its #392 holding.
Sculptor Capital first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 17 quarters since.
Sculptor Capital's Aspire Biopharma Warrant position peaked at $80K in Q2 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Sculptor Capital's 13F filing for Q2 2026, filed 14 Aug 2026.